Conference Day Two
8:00 am Morning Coffee
8:45 am Chair’s Opening Remarks
Engineering the Microbiome to Increase Durability
9:00 am Overcoming Analytical Challenges & Solutions in Engineered Microbiome Therapies
Synopsis
- Analytical challenges for testing microbiome therapeutics to enable clinical and commercial use
- Potential approaches for measuring potency, purity, and stability of live bacterial products
- Expectations for validations of analytical methods
9:30 am Increasing Durability & Persistence in Microbiome-Based Therapies
Synopsis
- Skin microbiome engineering and modulation
- Long term bacterial engraftment in the skin
- Skin microbiome mediate sebum secretion modulation
10:00 am Proteomics Driven Approaches for Increased Stability
Synopsis
- Synlogic is a clinical-stage biotechnology company harnessing Escherichia coli Nissle as a livebiotherapeutic product (LBP) for delivery of therapies for under-served metabolic diseases such as phenylketonuria (PKU) and homocystinuria (HCU)
- We are assessing the use of various ‘-omics’ technologies as a tool to better understand manufacturing, stability and activity of our lyophilized LBP. In the present work, we aim to utilize mass spectrometry-based proteomics to assess the role of protein oxidation in product stability
- Insights have led to development of process-based changes and changes during varied fermentation batch processes which report nutrient limitation unnoticeable by typical fermentation sensors
10:30 am Morning Break
Increasing Control with mRNA Genetic Circuits & Multicellular Engineering
11:30 am Programmable mRNA-Encoded Genetic Circuits for Cancer Immunotherapy
Synopsis
- Development of synthetic genetic circuits for use with RNA therapeutics
- Dosing of therapeutic protein without impacting therapeutic index of the payload
12:00 pm Enhancing Multicellular Engineering with Synthetic Biology
Synopsis
- Harnessing gene editing tools for precise manipulation of organoid cells
- Introducing synthetic gene circuits to enhance multicellular communication and behavior
- Interfacing with other modalities including biomaterials
12:30 pm Lunch
Synthetic Biology Enhancements to Maximize on the Potential of Cell Therapies
1:30 pm Translating Synthetic Biology Innovations into Cell Therapy Products
Synopsis
- Identifying opportunities and challenges in the cell therapy field
- Exploring the disruptive potential of synthetic biology in overcoming these challenges
- Optimizing the design-build-test-learn cycle to accelerate therapies to the clinic
2:00 pm Maximizing Antitumor Activity with Weaponized CAR-T Therapies
Synopsis
- Optimizing CAR-T cell functionality and persistence in the tumor microenvironment
- Leveraging rational design and directed evolution, to fine-tune CAR constructs
- Harnessing synthetic biology-based gene circuits to program CAR-T cell responses, enabling precise control over activation, proliferation, and persistence
2:30 pm Enhancing Tumor Eradication Using Synthetic Biology Powered CAR-T Therapies
Synopsis
- Optimizing CAR-T cell functionality and persistence in the tumor microenvironment
- Overcoming systemic cytokines toxicities of CAR-T cells
- Harnessing synthetic biology-based gene circuits to program CAR-T cell responses, enabling precise control over activation, proliferation, and persistence
3:00 pm Afternoon Break & Networking
Elucidating Investment & Future Directions from Industry to Academia
3:30 pm Investors Panel: Navigating Investment Opportunities in Synthetic Biology-Based Therapies
Synopsis
- Insights from industry-leading investors on the potential and most promising applications commercially of synthetic biology in therapeutics
- Identifying attractive investment opportunities and industry trends
- Strategies for successful investment and collaboration in the synthetic biology space
4:00 pm Leveraging the Conamax system to Open New Markets for Therapeutic Monoclonal Antibodies
Synopsis
- Critical quality attributes required of therapeutic monoclonal antibodies
- Challenges in meeting these requirements when producing mAbs in microbial systems
- Strategies for improving N-glycan occupancy and humanizing N-glycan structures in a novel microbial host for mAb expression
4:30 pm Panel: Shaping the Future of Synthetic Biology Therapies with Translatable Approaches
Synopsis
- Insights from academia on the emerging trends and future directions in synthetic biology
- Exploring groundbreaking research and its potential impact on therapeutic applications
- Collaborating with academia to drive innovation and translate scientific advancements into real-world, implementable
- solutions